StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.90−0.05 (-4.77%)

Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –

Spero Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Spero Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $6.03M. For fiscal 2025 it was $6.31M. The highest annual figure on record is $21.48M in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.31M–
FY2024Dec 31, 2024-$73.36M-441.5%
FY2023Dec 31, 2023$21.48M–
FY2022Dec 31, 2022-$42.20M–
FY2021Dec 31, 2021-$87.97M–
FY2020Dec 31, 2020-$79.11M–
FY2019Dec 31, 2019-$63.22M–
FY2018Dec 31, 2018-$42.81M–
FY2017Dec 31, 2017-$41.73M–
FY2016Dec 31, 2016-$33.22M–
FY2015Dec 31, 2015-$13.33M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.93M–
Q1 FY2026Mar 31, 2026-$7.54M–
Q4 FY2025Dec 31, 2025$31.41M–
Q3 FY2025Sep 30, 2025-$7.92M–
Q2 FY2025Jun 30, 2025-$2.44M–
Q1 FY2025Mar 31, 2025-$14.73M–
Q4 FY2024Dec 31, 2024-$21.73M-143.0%
Q3 FY2024Sep 30, 2024-$18.59M–
Q2 FY2024Jun 30, 2024-$19.06M–
Q1 FY2024Mar 31, 2024-$13.98M–
Q4 FY2023Dec 31, 2023$50.53M+94.9%
Q3 FY2023Sep 30, 2023-$1.93M–
Q2 FY2023Jun 30, 2023-$12.89M–
Q1 FY2023Mar 31, 2023-$14.23M–
Q4 FY2022Dec 31, 2022$25.92M–
Q3 FY2022Sep 30, 2022-$11.83M–
Q2 FY2022Jun 30, 2022-$26.08M–
Q1 FY2022Mar 31, 2022-$30.21M–
Q4 FY2021Dec 31, 2021-$27.50M–
Q3 FY2021Sep 30, 2021-$22.52M–
Q2 FY2021Jun 30, 2021-$18.54M–
Q1 FY2021Mar 31, 2021-$19.40M–
Q4 FY2020Dec 31, 2020-$18.80M–
Q3 FY2020Sep 30, 2020-$19.02M–
Q2 FY2020Jun 30, 2020-$18.48M–
Q1 FY2020Mar 31, 2020-$22.82M–
Q4 FY2019Dec 31, 2019-$25.88M–
Q3 FY2019Sep 30, 2019-$17.99M–
Q2 FY2019Jun 30, 2019-$13.65M–
Q1 FY2019Mar 31, 2019-$5.70M–
Q4 FY2018Dec 31, 2018-$11.08M–
Q3 FY2018Sep 30, 2018-$10.94M–
Q2 FY2018Jun 30, 2018-$9.97M–
Q1 FY2018Mar 31, 2018-$10.82M–
Q4 FY2017Dec 31, 2017-$14.00M–
Q3 FY2017Sep 30, 2017-$9.97M–
Q2 FY2017Jun 30, 2017-$10.17M–
Q1 FY2017Mar 31, 2017-$7.60M–
Q4 FY2016Dec 31, 2016-$8.81M–
Q3 FY2016Sep 30, 2016-$7.91M–

More Spero Therapeutics figures

See a number that looks wrong?